Does a four-week delay in the introduction of medication alter the course of functional psychosis?
This study is an analysis of findings of a follow-up study of 105 patients with functional psychotic illness who had participated in a random and blind 4-week trial of pimozide, lithium, both and placebo. The intention was to examine the question of whether a 4-week delay in initiating antipsychotic...
Gespeichert in:
| Veröffentlicht in: | Journal of psychopharmacology (Oxford) 1999-05, Vol.13 (3), p.238-244 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 244 |
|---|---|
| container_issue | 3 |
| container_start_page | 238 |
| container_title | Journal of psychopharmacology (Oxford) |
| container_volume | 13 |
| creator | Johnstone, Eve C. Owens, David G. C. Crow, Timothy J. Davis, John M. |
| description | This study is an analysis of findings of a follow-up study of 105 patients with functional psychotic illness who had participated in a random and blind 4-week trial of pimozide, lithium, both and placebo. The intention was to examine the question of whether a 4-week delay in initiating antipsychotic treatment has a detrimental effect 2.5 years later. Detailed follow-up measures included need for care over the 2.5 years, treatments required, occupational decline, police contact, substance misuse, psychopathology and cognitive function. There was no evidence at all that those initially randomized to placebo had a poorer outcome in terms of any of these variables. It is concluded that a 4-week delay in initiating active treatment in patients with functional psychosis has no long-term adverse effects. |
| doi_str_mv | 10.1177/026988119901300305 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_746271837</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_026988119901300305</sage_id><sourcerecordid>1979971492</sourcerecordid><originalsourceid>FETCH-LOGICAL-c428t-2e1134d674aa6e3fe72f04247816f477b0cbfc60dfb39ea3ff74665bd795a2423</originalsourceid><addsrcrecordid>eNp10c1O3DAQAGALFcHy8wIcqkhF4pTicRw7PlWIFqiExKU9R44zhtBsvHgSoX37Orsrgah6Gln-ZjyeYewM-FcArS-5UKaqAIzhUHBe8HKPLUAqyLWoyk9sMYN8FofsiOiZc1BSlQfsEHgJgutqwZrvASmzmQ9TzF8R_2Qt9naddUM2PmEKYwzt5MYuDFnw2RLbztnNyfYjxg1yKZdwvvbTsKG2z1a0dk-BOvp2wva97QlPd_GY_b758ev6Lr9_uP15fXWfOymqMRcIUMhWaWmtwsKjFp5LIXUFykutG-4a7xRvfVMYtIX3WipVNq02pRVSFMfsYlt3FcPLhDTWy44c9r0dMExUJy40VIVO8ssH-Zy-kLqmGow2RoM0cz2xVS4Gooi-XsVuaeO6Bl7PC6j_XUBK-rwrPTVpWO9SthNP4HwHLDnb-2gH19GbM7LklUrscsvIPuK79v7_8l9DjZnj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1979971492</pqid></control><display><type>article</type><title>Does a four-week delay in the introduction of medication alter the course of functional psychosis?</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Johnstone, Eve C. ; Owens, David G. C. ; Crow, Timothy J. ; Davis, John M.</creator><creatorcontrib>Johnstone, Eve C. ; Owens, David G. C. ; Crow, Timothy J. ; Davis, John M.</creatorcontrib><description>This study is an analysis of findings of a follow-up study of 105 patients with functional psychotic illness who had participated in a random and blind 4-week trial of pimozide, lithium, both and placebo. The intention was to examine the question of whether a 4-week delay in initiating antipsychotic treatment has a detrimental effect 2.5 years later. Detailed follow-up measures included need for care over the 2.5 years, treatments required, occupational decline, police contact, substance misuse, psychopathology and cognitive function. There was no evidence at all that those initially randomized to placebo had a poorer outcome in terms of any of these variables. It is concluded that a 4-week delay in initiating active treatment in patients with functional psychosis has no long-term adverse effects.</description><identifier>ISSN: 0269-8811</identifier><identifier>EISSN: 1461-7285</identifier><identifier>DOI: 10.1177/026988119901300305</identifier><identifier>PMID: 10512078</identifier><language>eng</language><publisher>London, Thousand Oaks, CA and New Delhi: SAGE Publications</publisher><subject>Adolescent ; Adult ; Antimanic Agents - adverse effects ; Antimanic Agents - therapeutic use ; Antipsychotic Agents - administration & dosage ; Antipsychotic Agents - adverse effects ; Antipsychotic Agents - therapeutic use ; Antipsychotics ; Biological and medical sciences ; Cognitive ability ; Double-Blind Method ; Employment ; Female ; Follow-Up Studies ; Humans ; Lithium ; Lithium - adverse effects ; Lithium - therapeutic use ; Male ; Medical sciences ; Mental disorders ; Middle Aged ; Motivation ; Neuropharmacology ; Pharmacology. Drug treatments ; Pimozide - adverse effects ; Pimozide - therapeutic use ; Police ; Prognosis ; Psychiatric Status Rating Scales ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology ; Psychopharmacology ; Psychosis ; Psychotic Disorders - drug therapy ; Time Factors</subject><ispartof>Journal of psychopharmacology (Oxford), 1999-05, Vol.13 (3), p.238-244</ispartof><rights>1999 INIST-CNRS</rights><rights>Copyright Sage Publications Ltd. May 1999</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c428t-2e1134d674aa6e3fe72f04247816f477b0cbfc60dfb39ea3ff74665bd795a2423</citedby><cites>FETCH-LOGICAL-c428t-2e1134d674aa6e3fe72f04247816f477b0cbfc60dfb39ea3ff74665bd795a2423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/026988119901300305$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/026988119901300305$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21819,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1945086$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10512078$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Johnstone, Eve C.</creatorcontrib><creatorcontrib>Owens, David G. C.</creatorcontrib><creatorcontrib>Crow, Timothy J.</creatorcontrib><creatorcontrib>Davis, John M.</creatorcontrib><title>Does a four-week delay in the introduction of medication alter the course of functional psychosis?</title><title>Journal of psychopharmacology (Oxford)</title><addtitle>J Psychopharmacol</addtitle><description>This study is an analysis of findings of a follow-up study of 105 patients with functional psychotic illness who had participated in a random and blind 4-week trial of pimozide, lithium, both and placebo. The intention was to examine the question of whether a 4-week delay in initiating antipsychotic treatment has a detrimental effect 2.5 years later. Detailed follow-up measures included need for care over the 2.5 years, treatments required, occupational decline, police contact, substance misuse, psychopathology and cognitive function. There was no evidence at all that those initially randomized to placebo had a poorer outcome in terms of any of these variables. It is concluded that a 4-week delay in initiating active treatment in patients with functional psychosis has no long-term adverse effects.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antimanic Agents - adverse effects</subject><subject>Antimanic Agents - therapeutic use</subject><subject>Antipsychotic Agents - administration & dosage</subject><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Antipsychotics</subject><subject>Biological and medical sciences</subject><subject>Cognitive ability</subject><subject>Double-Blind Method</subject><subject>Employment</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Lithium</subject><subject>Lithium - adverse effects</subject><subject>Lithium - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mental disorders</subject><subject>Middle Aged</subject><subject>Motivation</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Pimozide - adverse effects</subject><subject>Pimozide - therapeutic use</subject><subject>Police</subject><subject>Prognosis</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology</subject><subject>Psychopharmacology</subject><subject>Psychosis</subject><subject>Psychotic Disorders - drug therapy</subject><subject>Time Factors</subject><issn>0269-8811</issn><issn>1461-7285</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10c1O3DAQAGALFcHy8wIcqkhF4pTicRw7PlWIFqiExKU9R44zhtBsvHgSoX37Orsrgah6Gln-ZjyeYewM-FcArS-5UKaqAIzhUHBe8HKPLUAqyLWoyk9sMYN8FofsiOiZc1BSlQfsEHgJgutqwZrvASmzmQ9TzF8R_2Qt9naddUM2PmEKYwzt5MYuDFnw2RLbztnNyfYjxg1yKZdwvvbTsKG2z1a0dk-BOvp2wva97QlPd_GY_b758ev6Lr9_uP15fXWfOymqMRcIUMhWaWmtwsKjFp5LIXUFykutG-4a7xRvfVMYtIX3WipVNq02pRVSFMfsYlt3FcPLhDTWy44c9r0dMExUJy40VIVO8ssH-Zy-kLqmGow2RoM0cz2xVS4Gooi-XsVuaeO6Bl7PC6j_XUBK-rwrPTVpWO9SthNP4HwHLDnb-2gH19GbM7LklUrscsvIPuK79v7_8l9DjZnj</recordid><startdate>199905</startdate><enddate>199905</enddate><creator>Johnstone, Eve C.</creator><creator>Owens, David G. C.</creator><creator>Crow, Timothy J.</creator><creator>Davis, John M.</creator><general>SAGE Publications</general><general>Sage</general><general>Sage Publications Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>199905</creationdate><title>Does a four-week delay in the introduction of medication alter the course of functional psychosis?</title><author>Johnstone, Eve C. ; Owens, David G. C. ; Crow, Timothy J. ; Davis, John M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c428t-2e1134d674aa6e3fe72f04247816f477b0cbfc60dfb39ea3ff74665bd795a2423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antimanic Agents - adverse effects</topic><topic>Antimanic Agents - therapeutic use</topic><topic>Antipsychotic Agents - administration & dosage</topic><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Antipsychotics</topic><topic>Biological and medical sciences</topic><topic>Cognitive ability</topic><topic>Double-Blind Method</topic><topic>Employment</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Lithium</topic><topic>Lithium - adverse effects</topic><topic>Lithium - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mental disorders</topic><topic>Middle Aged</topic><topic>Motivation</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Pimozide - adverse effects</topic><topic>Pimozide - therapeutic use</topic><topic>Police</topic><topic>Prognosis</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology</topic><topic>Psychopharmacology</topic><topic>Psychosis</topic><topic>Psychotic Disorders - drug therapy</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Johnstone, Eve C.</creatorcontrib><creatorcontrib>Owens, David G. C.</creatorcontrib><creatorcontrib>Crow, Timothy J.</creatorcontrib><creatorcontrib>Davis, John M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Journal of psychopharmacology (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Johnstone, Eve C.</au><au>Owens, David G. C.</au><au>Crow, Timothy J.</au><au>Davis, John M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Does a four-week delay in the introduction of medication alter the course of functional psychosis?</atitle><jtitle>Journal of psychopharmacology (Oxford)</jtitle><addtitle>J Psychopharmacol</addtitle><date>1999-05</date><risdate>1999</risdate><volume>13</volume><issue>3</issue><spage>238</spage><epage>244</epage><pages>238-244</pages><issn>0269-8811</issn><eissn>1461-7285</eissn><abstract>This study is an analysis of findings of a follow-up study of 105 patients with functional psychotic illness who had participated in a random and blind 4-week trial of pimozide, lithium, both and placebo. The intention was to examine the question of whether a 4-week delay in initiating antipsychotic treatment has a detrimental effect 2.5 years later. Detailed follow-up measures included need for care over the 2.5 years, treatments required, occupational decline, police contact, substance misuse, psychopathology and cognitive function. There was no evidence at all that those initially randomized to placebo had a poorer outcome in terms of any of these variables. It is concluded that a 4-week delay in initiating active treatment in patients with functional psychosis has no long-term adverse effects.</abstract><cop>London, Thousand Oaks, CA and New Delhi</cop><pub>SAGE Publications</pub><pmid>10512078</pmid><doi>10.1177/026988119901300305</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-8811 |
| ispartof | Journal of psychopharmacology (Oxford), 1999-05, Vol.13 (3), p.238-244 |
| issn | 0269-8811 1461-7285 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_746271837 |
| source | Access via SAGE; MEDLINE |
| subjects | Adolescent Adult Antimanic Agents - adverse effects Antimanic Agents - therapeutic use Antipsychotic Agents - administration & dosage Antipsychotic Agents - adverse effects Antipsychotic Agents - therapeutic use Antipsychotics Biological and medical sciences Cognitive ability Double-Blind Method Employment Female Follow-Up Studies Humans Lithium Lithium - adverse effects Lithium - therapeutic use Male Medical sciences Mental disorders Middle Aged Motivation Neuropharmacology Pharmacology. Drug treatments Pimozide - adverse effects Pimozide - therapeutic use Police Prognosis Psychiatric Status Rating Scales Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopathology Psychopharmacology Psychosis Psychotic Disorders - drug therapy Time Factors |
| title | Does a four-week delay in the introduction of medication alter the course of functional psychosis? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T05%3A04%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Does%20a%20four-week%20delay%20in%20the%20introduction%20of%20medication%20alter%20the%20course%20of%20functional%20psychosis?&rft.jtitle=Journal%20of%20psychopharmacology%20(Oxford)&rft.au=Johnstone,%20Eve%20C.&rft.date=1999-05&rft.volume=13&rft.issue=3&rft.spage=238&rft.epage=244&rft.pages=238-244&rft.issn=0269-8811&rft.eissn=1461-7285&rft_id=info:doi/10.1177/026988119901300305&rft_dat=%3Cproquest_cross%3E1979971492%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1979971492&rft_id=info:pmid/10512078&rft_sage_id=10.1177_026988119901300305&rfr_iscdi=true |